Predicting Colectomy and Post-Op Mortality in C. Difficile Colitis Patients

To analyze the risk factors for colectomy and post-operative mortality among Clostridium difficile colitis (CDC) patients, a group of surgeons retrospectively reviewed CDC trends between 2001 and 2010.

Epidemiologists have been documenting an increasing incidence of Clostridium difficile colitis (CDC) in the United States, and many affected patients must undergo total colectomy.

To analyze the risk factors for colectomy and post-operative mortality among those patients, surgeons from the University of California, Irvine School of Medicine retrospectively reviewed the Nationwide Inpatient Sample (NIS) between 2001 and 2010 for CDC trends.

During the 10-year review period, more than 2.7 million hospital discharges with a diagnosis of CDC were identified. The researchers found that colectomy was needed in 0.7% of those patients, among whom roughly 1 in 3 died.

The authors identified coagulopathy (OR 2.71), weight loss (OR 2.25), admission to teaching hospitals (OR 1.37), fluid or electrolyte disorders (OR 1.31), and admission to large hospitals (OR 1.18) as predictors for colectomy. Risk factors for mortality after colectomy included coagulopathy (odds ratio [OR] 2.38), age older than 60 years (OR 1.97), acute renal failure (OR 1.67), respiratory failure (OR 1.61), sepsis (OR 1.40), peripheral vascular disease (OR 1.39), and congestive heart failure (OR 1.25). In addition, surgery performed more than 3 days after admission was associated with higher mortality rates (OR 1.09).

The study also identified protective factors for CDC patients requiring colectomy, such as obesity, hypothyroidism, depression, deficiency anemia, drug abuse, weight loss, and blood loss anemia.

The researchers advised clinicians who are aware of specific predisposing patient and hospital factors to apply their knowledge in order to risk-stratify and counsel CDC patients appropriately. Those at highest risk should be quickly referred for colectomy.

Related Videos
Esther Ellen Freeman, MD, PhD: Current Mpox Impact on the Skin
Jan Wehkamp, MD, PhD: Expanding the Studies of Ustekinumab for IBD
Jan Wehkamp, MD, PhD: New Long-Term Safety Data for Ustekinumab for Ulcerative Colitis
Maria T. Abreu, MD: Promising Initial Data on Guselkumab From ECCO 2023
Mustafa Özçam, PhD: Investigating Gut Microbiome in Children with Peanut Allergy
Planning Lung Cancer Screening, Surgery Between Clinicians and Patients
Jessica Allegretti, MD: Closing the Books on CP101
Laura Wingate: Improving All Aspects of Care for IBD Patients
© 2023 MJH Life Sciences

All rights reserved.